The Search for Multiple Myeloma Stem Cells: The Long and Winding Road

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 5, 2010, Pages 587-594

  Basak, Grzegorz Wladyslaw ^a,b   Carrier, Ewa ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Cancer stem cell; Clonotypic B cell; Leukemia stem cell; Myeloma

Indexed keywords

IMMUNOGLOBULIN M;

AUTOLOGOUS STEM CELL TRANSPLANTATION; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CANCER STEM CELL; CLONOTYPIC B LYMPHOCYTE; CYTOLOGY; HUMAN; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBPOPULATION; MULTIPLE MYELOMA; MULTIPLE MYELOMA STEM CELL; NONHUMAN; PLASMA CELL; REVIEW;

B-LYMPHOCYTES; CLONE CELLS; HUMANS; MULTIPLE MYELOMA; NEOPLASTIC STEM CELLS;

EID: 77951208932     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.10.024     Document Type: Review

References (55)

1. Dick J.E. Acute myeloid leukemia stem cells. Ann NY Acad Sci 2005, 1044:1-5.
2. Kvinlaug B.T., Huntly B.J. Targeting cancer stem cells. Expert Opin Ther Target 2007, 11:915-927.
3. Pan C.X., Zhu W., Cheng L. Implications of cancer stem cells in the treatment of cancer. Fut Oncol 2006, 2:723-731.
4. Guan Y., Gerhard B., Hogge D.E. Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). Blood 2003, 101:3142-3149.
5. Guan Y., Hogge D.E. Proliferative status of primitive hematopoietic progenitors from patients with acute myelogenous leukemia (AML). Leukemia 2000, 14:2135-2141.
6. Konopleva M., Zhao S., Hu W., et al. The anti-apoptotic genes Bcl-X(L) and Bcl-2 are over-expressed and contribute to chemoresistance of non-proliferating leukaemic CD34+ cells. Br J Haematol 2002, 118:521-534.
7. Ishikawa F., Yoshida S., Saito Y., et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 2007, 25:1315.
8. Luckey C.J., Bhattacharya D., Goldrath A.W., et al. Memory T and memory B cells share a transcriptional program of self-renewal with long-term hematopoietic stem cells. Proc Natl Acad Sci USA 2006, 103:3304-3309.
9. Kyle R.A., Rajkumar S.V. Multiple myeloma. N Engl J Med 2004, 351:1860-1873.
10. Basak G.W., Srivastava A., Malhotra R., et al. Multiple myeloma bone marrow niche. Curr Pharm Biotechnol 2009, 10:345-356.
11. Orlowski R.Z. Initial therapy of multiple myeloma patients who are not candidates for stem cell transplantation. Hematol Am Soc Hematol Educ Progr 2006, 338-347.
12. Pant S., Copelan E.A. Hematopoietic stem cell transplantation in multiple myeloma. Biol Blood Marrow Transplant 2007, 13:877-885.
13. Park C.H., Bergsagel D.E., McCulloch E.A. Mouse myeloma tumor stem cells: a primary cell culture assay. J Natl Cancer Inst 1971, 46:411-422.
14. Hamburger A., Salmon S.E. Primary bioassay of human myeloma stem cells. J Clin Invest 1977, 60:846-854.
15. Robillard N., Pellat-Deceunynck C., Bataille R. Phenotypic characterization of the human myeloma cell growth fraction. Blood 2005, 105:4845-4848.
16. Jensen G.S., Mant M.J., Belch A.J., et al. Selective expression of CD45 isoforms defines CALLA+ monoclonal B-lineage cells in peripheral blood from myeloma patients as late stage B cells. Blood 1991, 78:711-719.
17. Jensen G.S., Belch A.R., Kherani F., et al. Restricted expression of immunoglobulin light chain mRNA and of the adhesion molecule CD11b on circulating monoclonal B lineage cells in peripheral blood of myeloma patients. Scand J Immunol 1992, 36:843-853.
18. Bergsagel P.L., Masellis-Smith A., Belch A.R., et al. The blood B-cells and bone marrow plasma cells in patients with multiple myeloma share identical IgH rearrangements. Curr Top Microbiol Immunol 1995, 194:17-24.
19. Szczepek A.J., Seeberger K., Wizniak J., et al. A high frequency of circulating B cells share clonotypic Ig heavy-chain VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single-cell and in situ reverse transcriptase-polymerase chain reaction. Blood 1998, 92:2844-2855.
20. Berenson J.R., Vescio R.A., Hong C.H., et al. Multiple myeloma clones are derived from a cell late in B lymphoid development. Curr Top Microbiol Immunol 1995, 194:25-33.
21. Billadeau D., Ahmann G., Greipp P., et al. The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell. J Exp Med 1993, 178:1023-1031.
22. Jensen G.S., Mant M.J., Pilarski L.M. Sequential maturation stages of monoclonal B lineage cells from blood, spleen, lymph node, and bone marrow from a terminal myeloma patient. Am J Hematol 1992, 41:199-208.
23. Matsui W., Huff C.A., Wang Q., et al. Characterization of clonogenic multiple myeloma cells. Blood 2004, 103:2332-2336.
24. Bergsagel P.L., Smith A.M., Szczepek A., et al. In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain. Blood 1995, 85:436-447.
25. Rasmussen T., Lodahl M., Hancke S., et al. In multiple myeloma clonotypic CD38-/CD19+/CD27+ memory B cells recirculate through bone marrow, peripheral blood and lymph nodes. Leuk Lymphoma 2004, 45:1413-1417.
26. Masellis-Smith A., Belch A.R., Mant M.J., et al. Hyaluronan-dependent motility of B cells and leukemic plasma cells in blood, but not of bone marrow plasma cells, in multiple myeloma: alternate use of receptor for hyaluronan-mediated motility (RHAMM) and CD44. Blood 1996, 87:1891-1899.
27. Rasmussen T., Kastrup J., Knudsen L.M., et al. High numbers of clonal CD19+ cells in the peripheral blood of a patient with multiple myeloma. Br J Haematol 1999, 105:265-267.
28. Pilarski L.M., Jensen G.S. Monoclonal circulating B cells in multiple myeloma. A continuously differentiating, possibly invasive, population as defined by expression of CD45 isoforms and adhesion molecules. Hematol Oncol Clin North Am 1992, 6:297-322.
29. Turley E.A., Belch A.J., Poppema S., et al. Expression and function of a receptor for hyaluronan-mediated motility on normal and malignant B lymphocytes. Blood 1993, 81:446-453.
30. Pilarski L.M., Masellis-Smith A., Belch A.R., et al. RHAMM, a receptor for hyaluronan-mediated motility, on normal human lymphocytes, thymocytes and malignant B cells: a mediator in B cell malignancy?. Leuk Lymphoma 1994, 14:363-374.
31. Jensen G.S., Belch A.R., Mant M.J., et al. Expression of multiple beta 1 integrins on circulating monoclonal B cells in patients with multiple myeloma. Am J Hematol 1993, 43:29-36.
32. Sahota S.S., Garand R., Mahroof R., et al. V(H) gene analysis of IgM-secreting myeloma indicates an origin from a memory cell undergoing isotype switch events. Blood 1999, 94:1070-1076.
33. Pilarski L.M., Belch A.R. Clonotypic myeloma cells able to xenograft myeloma to nonobese diabetic severe combined immunodeficient mice copurify with CD34 + hematopoietic progenitors. Clin Cancer Res 2002, 8:3198-3204.
34. Corradini P., Boccadoro M., Voena C., et al. Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined to C mu sequence in immunoglobulin (IgG)- and IgA-secreting multiple myelomas. J Exp Med 1993, 178:1091-1096.
35. Bakkus M.H., Van Riet I., Van Camp B., et al. Evidence that the clonogenic cell in multiple myeloma originates from a pre-switched but somatically mutated B cell. Br J Haematol 1994, 87:68-74.
36. Reiman T., Seeberger K., Taylor B.J., et al. Persistent preswitch clonotypic myeloma cells correlate with decreased survival: evidence for isotype switching within the myeloma clone. Blood 2001, 98:2791-2799.
37. Taylor B.J., Kriangkum J., Pittman J.A., et al. Analysis of clonotypic switch junctions reveals multiple myeloma originates from a single class switch event with ongoing mutation in the isotype-switched progeny. Blood 2008, 112:1894-1903.
38. Pilarski L.M., Belch A.R. Circulating monoclonal B cells expressing P glycoprotein may be a reservoir of multidrug-resistant disease in multiple myeloma. Blood 1994, 83:724-736.
39. Pilarski L.M., Szczepek A.J., Belch A.R. Deficient drug transporter function of bone marrow-localized and leukemic plasma cells in multiple myeloma. Blood 1997, 90:3751-3759.
40. Gazitt Y., Tian E., Barlogie B., et al. Differential mobilization of myeloma cells and normal hematopoietic stem cells in multiple myeloma after treatment with cyclophosphamide and granulocyte-macrophage colony-stimulating factor. Blood 1996, 87:805-811.
41. Patriarca F., Damiani D., Fanin R., et al. High-dose therapy in multiple myeloma: effect of positive selection of CD34+ peripheral blood stem cells on hematologic engraftment and clinical outcome. Haematologica 2000, 85:269-274.
42. Bourhis J.H., Bouko Y., Koscielny S., et al. European Group for Blood and Marrow Transplantation. Relapse risk after autologous transplantation in patients with newly diagnosed myeloma is not related with infused tumor cell load and the outcome is not improved by CD34+ cell selection: long term follow-up of an EBMT phase III randomized study. Haematologica 2007, 92:1083-1090.
43. Stewart A.K., Vescio R., Schiller G., et al. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J Clin Oncol 2001, 19:3771-3779.
44. Pilarski L.M., Masellis-Smith A., Szczepek A., et al. Circulating clonotypic B cells in the biology of multiple myeloma: speculations on the origin of myeloma. Leuk Lymphoma 1996, 22:375-383.
45. Hideshima T., Bergsagel P.L., Kuehl W.M., et al. Advances in biology of multiple myeloma: clinical applications. Blood 2004, 104:607-618.
46. Pilarski L.M., Hipperson G., Seeberger K., et al. Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice. Blood 2000, 95:1056-1065.
47. Pilarski L.M., Seeberger K., Coupland R.W., et al. Leukemic B cells clonally identical to myeloma plasma cells are myelomagenic in NOD/SCID mice. Exp Hematol 2002, 30:221-228.
48. Peacock C.D., Wang Q., Gesell G.S., et al. Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc Natl Acad Sci USA 2007, 104:4048-4053.
49. Matsui W., Wang Q., Barber J.P., et al. Clonogenic myeloma progenitors, stem cell properties and drug resistance. Cancer Res 2008, 68:190-197.
50. Yaccoby S., Epstein J. The proliferative potential of myeloma plasma cells manifest in the SCID-hu host. Blood 1999, 94:3576-3582.
51. Yaccoby S. The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype. Clin Cancer Res 2005, 11:7599-7606.
52. Treon S.P., Pilarski L.M., Belch A.R., et al. CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. J Immunother 2002, 25:72-81.
53. Zojer N., Kirchbacher K., Vesely M., et al. Rituximab treatment provides no clinical benefit in patients with pretreated advanced multiple myeloma. Leuk Lymphoma 2006, 47:1103-1109.
54. McSweeney P.A., Wells D.A., Shults K.E., et al. Tumor-specific aneuploidy not detected in CD19 + B-lymphoid cells from myeloma patients in a multidimensional flow cytometric analysis. Blood 1996, 88:622-632.
55. Pullarkat S.T., Vardiman J.W., Slovak M.L., et al. Megakaryocytic blast crisis as a presenting manifestation of chronic myeloid leukemia. Leuk Res 2008, 32:1770-1775.